Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Trial Profile

Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Cytarabine; Dexamethasone; Hydrocortisone; Methotrexate; Mitoxantrone; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Onyx Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2016 Planned number of patients changed from 39 to 36.
    • 07 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 07 Dec 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top